Compare Abbott Laboratories (ABT) vs Blackrock Inc (BLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Blackrock Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Blackrock Inc trades at $1,007.5 (market cap $156.46B). The key difference: Abbott Laboratories and Blackrock Inc are close in size by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | BLK | |
|---|---|---|
Market Cap | $166.94B | $156.46B |
Sector | Health | Financials |
52-Week High | $136.62 | $1.20K |
52-Week Low | $82.57 | $922.90 |
Enterprise Value | $193.69B | $158.28B |
Dividend Yield | 2.63% | 2.27% |
Volume | — | 641,547 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
BlackRock (BLK) trades at $1,009.43, up 1.38% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $12.53 exceeding expectations. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights expansion into Nasdaq-100 ETFs and Bitcoin ETF offerings, positioning for growth in private markets and AI-driven demand.
Outlook remains positive with a consensus price target of $1,260, reflecting 25% upside. Key risks include volatile cash flows and competitive pressures in ETF markets. Institutional sentiment is strongly bullish, with 76% of analysts rating Buy. Earnings on July 15 will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →
